Beta Bionics, Inc. (BBNX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-21

Key Insights

Beta Bionics filed a routine Q1 2026 earnings announcement on April 21, 2026, disclosing financial results for the period ended March 31, 2026 through a press release attachment.
The company is classified as an emerging growth company, which provides certain regulatory relief and reduced disclosure obligations under securities laws.
The filing contains minimal substantive information within the 8-K itself, with all financial details relegated to the non-filed press release exhibit, limiting investor access to officially filed disclosures.

Want the newest filings?

This analysis covers the filing from 2026-04-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-17

Beta Bionics, Inc. (BBNX) announced its Q4 and full-year 2025 financial results, potentially providing investors with insight into the company's recent performance.
The filing does not mention any material agreements, leadership changes, or other significant corporate events, suggesting a routine quarterly earnings report.
As an emerging growth company, Beta Bionics may have elected to take advantage of extended transition periods for complying with new or revised financial accounting standards, which could impact the company's financial reporting.

Filed: 2026-01-30

The company received a warning letter from the FDA citing deficiencies in its Quality Management System, Medical Device Reporting, and Correction and Removals, which may lead to further regulatory action if not resolved.
The company is preparing a written response to the FDA and has already implemented some corrective actions, but there is uncertainty around the timeline for resolution and the FDA's satisfaction with the company's response.
Despite the regulatory issues, the company still expects to launch the commercialization of its Mint product by the end of 2027, indicating the potential impact may be limited.

Filed: 2026-01-08

Beta Bionics, Inc. has issued preliminary, unaudited fourth quarter 2025 topline financial results, indicating the company's performance and progress during the quarter.
The company's common stock is traded on the Nasdaq Global Market under the ticker symbol BBNX, providing investors with a publicly traded investment opportunity.
Beta Bionics, Inc. has identified itself as an emerging growth company, which may allow it to take advantage of certain regulatory exemptions and reporting requirements.

Other reports for Beta Bionics, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.